Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors

Chemical Biology and Drug Design

Volumn 81, Issue 5, 2013, Pages 607-614

  Nichols, Daniel B ^a   Leão, Raquel A C ^b   Basu, Amartya ^a   Chudayeu, Maksim ^a   de Moraes, Paula De F ^b   Talele, Tanaji T ^c   Costa, Paulo R R ^b   Kaushik Basu, Neerja ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c ST JOHN'S UNIVERSITY   (United States)

Author keywords

Antiviral agents; Coumarin; HCV NS5B polymerase; Hepatitis C; Neoflavone

Indexed keywords

COUMARIN DERIVATIVE; FLAVONE DERIVATIVE; MUTANT PROTEIN; NEOFLAVONE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; PHLOROGLUCINOL; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG SCREENING; HEPATITIS C VIRUS; IC 50; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANTICOAGULANTS; ANTIVIRAL AGENTS; BINDING SITES; COUMARINS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLAVONES; HEPACIVIRUS; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84876836328     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12105     Document Type: Article

References (51)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science;244:359-362.
2. Houghton M., Weiner A., Han J., Kuo G., Choo Q.L. (1991) Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology;14:381-388.
3. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., Meeks E.L., Beach M.J. (1992) The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med;327:1899-1905.
4. Williams R. (2006) Global challenges in liver disease. Hepatology;44:521-526.
5. Ferenci P. (2006) Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol Dietol;52:157-174.
6. Pawlotsky J.M. (2006) Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol;299:261-284.
7. Feld J.J., Liang T.J. (2005) HCV persistence: cure is still a four letter word. Hepatology;41:23-25.
8. Sheridan C. (2011) New Merck and Vertex drugs raise standard of care in hepatitis C. Nat Biotechnol;29:553-554.
9. Rice C. (2011) Perspective: miles to go before we sleep. Nature;474:S8.
10. Garber K. (2011) Hepatitis C: move over interferon. Nat Biotechnol;29:963-966.
11. Behrens S.E., Tomei L., De Francesco R. (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J;15:12-22.
12. Moradpour D., Brass V., Bieck E., Friebe P., Gosert R., Blum H.E., Bartenschlager R., Penin F., Lohmann V. (2004) Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J Virol;78:13278-13284.
13. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. (2000) Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol;74:2046-2051.
14. Kwong A.D., McNair L., Jacobson I., George S. (2008) Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol;8:522-531.
15. De Francesco R., Rice C.M. (2003) New therapies on the horizon for hepatitis C: are we close? Clin Liver Dis;7:211-242, xi.
16. Barreca M.L., Iraci N., Manfroni G., Cecchetti V. (2011) Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Med Chem;3:1027-1055.
17. Bressanelli S., Tomei L., Rey F.A., De Francesco R. (2002) Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol;76:3482-3492.
18. Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L., Mathieu M., De Francesco R., Rey F.A. (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA;96:13034-13039.
19. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., Weber P.C. (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol;6:937-943.
20. Ago H., Adachi T., Yoshida A., Yamamoto M., Habuka N., Yatsunami K., Miyano M. (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure;7:1417-1426.
21. Furman P.A., Lam A.M., Murakami E. (2009) Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. Future Med Chem;1:1429-1452.
22. Hang J.Q., Yang Y., Harris S.F., Leveque V., Whittington H.J., Rajyaguru S., Ao-Ieong G., McCown M.F., Wong A., Giannetti A.M., Le Pogam S., Talamás F., Cammack N., Nájera I., Klumpp K. (2009) Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem;284:15517-15529.
23. Wang M., Ng K.K., Cherney M.M., Chan L., Yannopoulos C.G., Bedard J., Morin N., Nguyen-Ba N., Alaoui-Ismaili M.H., Bethell R.C., James M.N. (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem;278:9489-9495.
24. Vermehren J., Sarrazin C. (2011) New HCV therapies on the horizon. Clin Microbiol Infect;17:122-134.
25. Kaushik-Basu N., Bopda-Waffo A., Talele T.T., Basu A., Costa P.R., da Silva A.J., Sarafianos S.G., Noël F. (2008) Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res;36:1482-1496.
26. Pocas E.S., Lopes D.V., da Silva A.J., Pimenta P.H., Leitao F.B., Netto C.D., Buarque C.D., Brito F.V., Costa P.R., Noël F. (2006) Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+ -ATPase and binding to the central benzodiazepine receptor. Bioorg Med Chem;14:7962-7966.
27. Riveiro M.E., De Kimpe N., Moglioni A., Vazquez R., Monczor F., Shayo C., Davio C. (2010) Coumarins: old compounds with novel promising therapeutic perspectives. Curr Med Chem;17:1325-1338.
28. Wu L., Wang X., Xu W., Farzaneh F., Xu R. (2009) The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem;16:4236-4260.
29. Borges F., Roleira F., Milhazes N., Santana L., Uriarte E. (2005) Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem;12:887-916.
30. Chouhan H.S., Singh S.K. (2011) A review of plants of genus Leucas. Pharmacogn Rev;3:13-26.
31. Leao R.A.C., de Moraes P.D.F., Pedro M.C.B.C., Costa P.R.R. (2011) Synthesis of coumarins and neoflavones through zinc chloride-catalyzed hydroarylation of acetylenic esters with phenols. Synthesis;22:3692-3696.
32. Ahluwalia V.K., Seshadri T.R., Venkateswarlu P. (1972) Nuclear allylation of hydroxycoumarins. II. Allylation of 5, 7-dihydroxy-4-phenylcoumarin and 5, 7-dihydroxycoumarin. Indian J Chem;10:260-262.
33. Goswami S., Gupta V.K., Gupta B.D., Sivakumar K. (2006) Synthesis and crystal structure of synthesis and crystal structure of 5, 7-diallyloxy-4-methylcoumarin. J Chem Crystallogr;36:77-82.
34. Suratwala T., Gardlund Z., Davidson K., Uhlmann D.R. (1998) Silylated coumarin dyes in sol-gel hosts. 1. Structure and environmental factors on fluorescent properties. Chem Mater;10:190-198.
35. Caffieri S., Moor A.C.E., Beijersbergen van Henegouwen G.M.J., Dall'Acqua F., Guiotto A., Chilin A., Rodighiero P. (1995) Difurocoumarins, psoralen analogs: synthesis and DNA photobinding. Z Naturforsch;50:1257-1264.
36. Ahuja M., Seshadri T.R. (1974) Claisen migration in substituted 4-phenylcoumarins. Indian J Chem;12:292-294.
37. Fan G., Mar W., Park M.K., Choi E.W., Kim K., Kim S. (2001) A novel class of inhibitors for steroid 5alpha-reductase: synthesis and evaluation of umbelliferone derivatives. Bioorg Med Chem Lett;11:2361-2363.
38. Chaudhuri S.K., Roy S., Bhar S. (2012) Dioxane dibromide mediated bromination of substituted coumarins under solvent-free conditions. Beilstein J Org Chem;8:323-329.
39. Chilin A., Manzini P., Caffieri S., Rodighiero P., Guiotto A. (2001) Difurocoumarins: psoralen analogs as photochemotherapeutic agents. J Heterocycl Chem;38:431-434.
40. Chattopadhyay S.K., Neogi K., Singha S.K., Dey R. (2008) Sequential Claisen rearrangement and intramolecular Heck reaction as a route to medium-ring oxacycle-fused heterocycles. Synlett;8:1137-1140.
41. Clarke D.J., Robinson R.S. (2002) Synthesis of thio- and oxo-analogues of isopsoralen. Tetrahedron;58:2831-2837.
42. Chattopadhyay S.K., Maity S., Panja S. (2002) Combined Claisen rearrangement and ring-closing metathesis as a route to oxepin- and oxocin-annulated coumarins. Tetrahedron Lett;43:7781-7783.
43. Kaushik-Basu N., Bopda-Waffo A., Talele T.T., Basu A., Chen Y., Kucukguzel S.G. (2008) 4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors. Front Biosci;13:3857-3868.
44. Chen Y., Bopda-Waffo A., Basu A., Krishnan R., Silberstein E., Taylor D.R., Talele T.T., Arora P., Kaushik-Basu N. (2009) Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor. Antivir Chem Chemother;20:19-36.
45. Nichols D.B., Fournet G., Gurukumar K.R., Basu A., Lee J.C., Sakamoto N., Kozielski F., Musmuca I., Joseph B., Ragno R., Kaushik-Basu N. (2012) Inhibition of hepatitis C virus NS5B polymerase by S-trityl-l-cysteine derivatives. Eur J Med Chem;49C:191-199.
46. Cheng C.C., Shipps G.W. Jr, Yang Z., Kawahata N., Lesburg C.A., Duca J.S., Bandouveres J., Bracken J.D., Jiang C.K., Agrawal S., Ferrari E., Huang H.C. (2010) Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides. Bioorg Med Chem Lett;20:2119-2124.
47. Betzi S., Eydoux C., Bussetta C., Blemont M., Leyssen P., Debarnot C., Ben-Rahou M. et al. (2009) Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antiviral Res;84:48-59.
48. Narjes F., Crescenzi B., Ferrara M., Habermann J., Colarusso S., Ferreira Mdel R., Stansfield I. et al. (2011) Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7, 8-dihydro-6H-indolo[1, 2-e][1, 5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem;54:289-301.
49. Li H., Tatlock J., Linton A., Gonzalez J., Jewell T., Patel L., Ludlum S. et al. (2009) Discovery of (R)-6-cyclopentyl-6-(2-(2, 6-diethylpyridin-4-yl)ethyl)-3-((5, 7-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5, 6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem;52:1255-1258.
50. Slater M.J., Amphlett E.M., Andrews D.M., Bravi G., Burton G., Cheasty A.G., Corfield J.A. et al. (2007) Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem;50:897-900.
51. Soriano V., Peters M.G., Zeuzem S. (2009) New therapies for hepatitis C virus infection. Clin Infect Dis;48:313-320.